Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Melanoma Immune Response Background Immune checkpoint inhibitors have made significant progress in clinical oncology, especially anti-PD-1 (anti-programmed death protein 1) and anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) therapies, which have been proven to induce long-term re...

TREM2 Deficiency Reprograms Gut Macrophages and Microbiota to Enhance Anti-PD-1 Tumor Immunotherapy Background Immune checkpoint inhibitors (CPIs), such as drugs that block programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), have been successfully used to activate anti...